{"id":429831,"date":"2025-09-17T13:55:15","date_gmt":"2025-09-17T13:55:15","guid":{"rendered":"https:\/\/www.europesays.com\/de\/429831\/"},"modified":"2025-09-17T13:55:15","modified_gmt":"2025-09-17T13:55:15","slug":"krebsimpfstoffe-werden-eine-wertvolle-therapieoption-werden","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/de\/429831\/","title":{"rendered":"Krebsimpfstoffe werden eine wertvolle Therapieoption werden"},"content":{"rendered":"<p>Impfstoffe gegen Krebs lassen sich prinzipiell in pr\u00e4ventive Impfstoffe, die bei Gesunden eingesetzt werden, und therapeutische unterscheiden, die f\u00fcr Krebspatienten gedacht sind. Ein Ziel beim pr\u00e4ventiven Ansatz sind krebserregende Viren: \u00bbEin Sechstel aller Krebserkrankungen wird von nur sieben Viren verursacht\u00ab. Dies seien Humane Papillomaviren (HPV), Hepatitis-B-Viren (HBV), Hepatitis-C-Viren (HCV), Epstein-Barr-Viren (EBV), Humane Herpes-Viren Typ 8 (HHV8), Humanes T-Zell-Leuk\u00e4mie-Viren Typ 1 (HTLV-1) und Merkelzell-Polyomaviren (MCPyV).<\/p>\n","protected":false},"excerpt":{"rendered":"Impfstoffe gegen Krebs lassen sich prinzipiell in pr\u00e4ventive Impfstoffe, die bei Gesunden eingesetzt werden, und therapeutische unterscheiden, die&hellip;\n","protected":false},"author":2,"featured_media":429832,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[137],"tags":[29,30,141,232],"class_list":{"0":"post-429831","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-gesundheit","8":"tag-deutschland","9":"tag-germany","10":"tag-gesundheit","11":"tag-health"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@de\/115219983549427171","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/429831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/comments?post=429831"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/posts\/429831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media\/429832"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/media?parent=429831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/categories?post=429831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/de\/wp-json\/wp\/v2\/tags?post=429831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}